Participant ID		
Initials of person	entering data	
Staff email		

CONFIDENTIAL CASE REPORT FORM

Opioids for symptomatic breathlessness Rapid Program Series No: 21

IMPACCT Trials Coordination Centre (ITCC)
UTS Rapid Program

The case report form (CRF) is to be completed in compliance with ITCC Standard Operating Procedures (SOP)

TABLE OF CONTENTS	PAGE NO.
T ₀ -Baseline	2
T ₁ - 2 days after baseline	9
T ₂ – 7-14 days after baseline	14
Medication Cessation	21
The Adhoc pages only need to be completed if an unexpected harm occurs outside of the assessment timepoints.	
Adhoc A	22
Adhoc B	25
Adhoc C	28

Baseline	(T ₀)				
Date of Ass	essment	DD/MN	DD/MM/YYYY		
Is the patient already on opioids for a reason other than breathlessness? ○ Yes - patient is excluded from this series ○ No - continue completing the CRF					
Demographi	Demographics (please tick)				
Gende r	○ Male	○ Female ○	Other Other		
					T
Age (yrs.)		Weight (kg)		Height (cm)	

Tick ✓	Primary life-limiting illness Please tick only one
	Advanced metastatic cancer
	End stage renal failure
	Hepatic failure
	Neurodegenerative disease
	Cardiac failure
	Respiratory failure
	AIDS
	Other; Please specify:

Tick ✓	Palliative Care Phase
	1. Stable Phase: The person's symptoms are adequately controlled by established management. Further interventions to maintain symptom control and quality of life have been planned.
	2. Unstable Phase: The person experiences the development of a new problem or a rapid increase in the severity of existing problems either of which requires an urgent change in management or emergency treatment.
	3. Deteriorating Phase: The person experiences a gradual worsening of existing symptoms or the development of new but expected problems. These require the application of specific plans of care and regular review but not urgent or emergency treatment.
	4. Terminal Care Phase: Death is likely in a matter of days and no acute intervention is planned or required.

Laboratory Tests (only if available)	
Test	Value
Haemoglobin (Hb) g/L	
Calculated Creatinine Clearance (CCr) (mL/min)	

(Charlson Comorbidity Index - Does the patient have any of the following? Please tick all that apply				
Tick		Tick	· · · ·		
	Myocardial Infarction (history, not ECG changes only)		Hemiplegia		
	Congestive Cardiac Failure		Moderate or Severe Renal Disease		
	Peripheral Vascular Disease (includes aortic aneurysm >= 6 cm)		Diabetes with End Organ Damage		
	Cerebrovascular Disease (CVA with mild or no residual or TIA)		Any Tumour		
	Dementia		Leukaemia (acute or chronic)		
	Chronic Pulmonary Disease		Lymphoma		
	Connective Tissue Disease		Moderate or Severe Liver Disease		
	Peptic Ulcer Disease		Metastatic Solid Tumour		
	Mild Liver Disease (without portal hypertension, includes chronic hepatitis)		AIDS (not just HIV positive)		
	Diabetes (without organ damage) (excludes diet-controlled alone)				

Tick ✓	Australian Modified Karnofsky Performance Scale (AKPS)		
	100 - Normal; no complaints; no evidence of disease		
	90 - Able to carry on normal activity; minor sign of symptoms of disease		
	80 - Normal activity with effort; some signs or symptoms of disease		
	70 - Cares for self; unable to carry on normal activity or to do active work		
	60 - Requires occasional assistance but is able to care for most needs		
	50 - Requires considerable assistance and frequent medical care		
	40 - In bed more than 50% of the time		
	30 - Almost completely bedfast		
	20 - Totally bedfast and requiring extensive nursing care by professionals and/or		
	family		
	10 - Comatose or barely rousable		
	0 - Dead		
	Not able to determine		

Baseline To - Medication Commencement

Tick ✓	Describe this episode of breathlessness in this patient.	
	Tick one	
	Treating established chronic breathlessness	
	An acute exacerbation on a background of chronic breathlessness	
	A new (<i>de novo</i>) episode of acute breathlessness	
	Other: Please specify here:	

Symptom Severity Scores *Please grade both symptoms; indicate that each harm has been assessed by ticking the square box above each.*

_	
[□ Breathlessness
(\bigcirc 1 \bigcirc 2 \bigcirc 3 \bigcirc 4 \bigcirc no symptom \bigcirc ungradable
	modified Medical Research Council (mMRC) breathlessness scale 0. Breathlessness only with strenuous exercise 1. Breathlessness when hurrying or walking up a slight hill 2. Walks slower than people of the same age because of breathlessness or has to stop for breath when walking at own pace 3. Stops for breath after walking 100 yards or after a few minutes 4. Too breathless to leave house or breathless when dressing or undressing
(\bigcirc 1 \bigcirc 2 \bigcirc 3 \bigcirc 4 \bigcirc 5 \bigcirc no symptom \bigcirc ungradable
	NCI Criteria 1: Mild symptoms; intervention not indicated 2: Moderate symptoms; limiting instrumental ADL 3: Severe symptoms; limiting self-care ADL; hospitalization not indicated 4: Life-threatening; hospitalization indicated 5: Death

Tick ✓	What other treatments (if any) is this person on for breathlessness? Tick all that apply	
	Benzodiazepine	
	Oxygen therapy	
	None	
	Other;(e.g., fan) please specify:	

Baseline Symptom/Harm Assessment

Please grade all harms; indicate that each harm has been assessed by ticking the square box above each

□ Dizziness
○ 1 ○ 2 ○ 3 ○ ungradable ○ No Symptom
NCI Criteria
1. Mild unsteadiness or sensation of movement
2.Moderate unsteadiness or sensation of movement; limiting instrumental ADL 3.Severe unsteadiness or sensation of movement; limiting self-care ADL
-
□ Nausea
○ 1 ○ 2 ○ 3 ○ ungradable ○ No Symptom NCI Criteria
1.Loss of appetite without alteration in eating habits
2.Oral intake decreased without significant weight loss, dehydration, or malnutrition
3.Inadequate oral caloric or fluid intake; tube feeding, TPN, or hospitalization indicated
\bigcirc 1 \bigcirc 2 \bigcirc 3 \bigcirc 4 \bigcirc 5 \bigcirc Ungradable \bigcirc No Symptom
NCI Criteria
Mild but more than usual drowsiness or sleepiness Madagate and thing limiting instrumental ARI
Moderate sedation; limiting instrumental ADL Obtundation or stupor
4. Life-threatening consequences; urgent intervention indicated
5. Death
\bigcirc 1 \bigcirc 2 \bigcirc 3 \bigcirc 4 \bigcirc 5 \bigcirc Ungradable \bigcirc No Symptom
NCI Criteria
1. Mild disorientation
2. Moderate disorientation; limiting instrumental ADL
Severe disorientation; limiting self-care ADL Life-threatening consequences threats of harm to self or others; hospitalization indicated
5. Death
□ Constipation
\bigcirc 1 \bigcirc 2 \bigcirc 3 \bigcirc 4 \bigcirc 5 \bigcirc ungradable \bigcirc no symptom
NCI Criteria
Mild; asymptomatic or mild symptoms
Moderate; minimal; local or non-invasive intervention indicated Severe or moderally significant but not immediately life threatening.
Severe or medically significant but not immediately life threatening Life threatening consequences; urgent intervention indicated
5. Death
What is the patient's respiratory rate
(breaths/min)
□ Other harm (only if applicable – can be related or unrelated to the medication)
Diagon and sife, other have have
Please specify other harm here
Other harms grade here.
○ 1 ○ 2 ○ 3 ○ 4 ○ 5 ○ Ungradable

□ Ad <i>medica</i>		I othei	harm	(only if	applicable – can be related or unrelated to the
	specify				here
			J		○ Ungradable

Tick ✓	Which symptom/harm is the most troublesome? (excluding the target symptoms of breathlessness and anxiety) (Tick one only)
	Dizziness
	Nausea
	Somnolence
	Confusion
	Respiratory Depression
	Constipation
	Other harm
	Additional other harm
	Not applicable

Baseline – T₀ – Medication Commencement

Date and Time of first dose of opioid administered for breathlessness							
Date	DD/MM/YYYY	Time (24-hr clock)	HH:MM				

Indicate which opioid(s) are being commenced for breathlessness. (If you are prescribing a regular opioid as well as PRN doses for breathlessness, please record in the separate tables provided:

ilas a <u>KLG</u>	Has a <u>REGULAR</u> opioid been commenced for breathlessness?					
○ Yes - please complete table below ○ No – proceed to PRN Opioid section						
	REGULAR OPIOID COMMENCEMENT					
Tick ✓	Name of regular opioid commenced for brea	thlessne	ss			
	Morphine					
	Oxycodone					
	Fentanyl					
	Buprenorphine					
	Tramadol					
	Tapentadol					
	Codeine					
	Hydromorphone					
	Other(s); please specify:					
Tick ✓	Route of administration/formulation					
Tick ✓	Route of administration/formulation Oral immediate release solution					
Tick ✓	•					
Tick ✓	Oral immediate release solution					
Tick ✓	Oral immediate release solution Oral immediate release tablet					
Tick ✓	Oral immediate release solution Oral immediate release tablet Oral extended-release tablet					
Tick ✓	Oral immediate release solution Oral immediate release tablet Oral extended-release tablet Subcutaneous					
Tick ✓	Oral immediate release solution Oral immediate release tablet Oral extended-release tablet Subcutaneous Intravenous					
Tick ✓	Oral immediate release solution Oral immediate release tablet Oral extended-release tablet Subcutaneous Intravenous Transdermal					
	Oral immediate release solution Oral immediate release tablet Oral extended-release tablet Subcutaneous Intravenous Transdermal Transmucosal Other; please specify: of REGULAR opioid prescribed in 24 hours					

AS NEEDED (PRN) OPIOID COMMENCEMENT Has a PRN opioid been commenced for breathlessness?							
◯ Yes - pl	ease complete tab	ole below O	No – no further	questions at this	s timepoint.		
Tick ✓	Indicate which breathlessness		nata/as need	led) opioid con	nmenced for		
	Morphine						
	Oxycodone						
	Fentanyl						
	Buprenorphine						
	Tramadol						
	Tapentadol						
	Codeine						
	Hydromorphone						
	Other(s); please	specify:					
T'ala /	Danie da danie	· · · · · · · · · · · · · · · · · · ·					
Tick ✓	Route of admir	nistration/forn	nulation				
	Oral immediate r	elease solution					
	Oral immediate release tablet						
	Oral extended-release tablet						
	Subcutaneous						
	Intravenous						
	Transdermal						
	Transmucosal						
	Other; please sp	ecify:					
DDN doso	prescribed by do	octor.					
PRIN GUSE	prescribed by do	octor.					
Unit of Measure: Tick whichever applies							
Frequency	of PRN dose pro	escribed (Pleas	se circle freque	ncy, or indicate of	other)		
Q1h	Q2h	Q3h	Q4h	Q6h	Q8h		
Q12	Other: Please	specify here:					
Maximum	number of dose	s of PRN allow	ed in 24-hou	r period:			

T ₁ -	2	day	/S	post	base	line

Tick ✓	T ₁ : Assessed/Not assessed reason			
	Assessed today (continue to complete T ₁) OR Died – record date of death below			
	Not able to be contacted / located			
	Too unwell Other			

Date of Death* DD/MM/YYYY

*End survey here

Date of T ₁ Assessment	DD/MM/YYYY
Time of Assessment (24-hr clock)	HH:MM

If T ₁ assessment is not within the timeframe above, please provide the reason
e.g. weekend

Symptom Severity Scores

Please grade both symptoms; indicate that each harm has been assessed by ticking the square box above each.

\Box	D.,,		1	necc
11	Kre	מדגי	IPSS	necc

 \bigcirc 1 \bigcirc 2 \bigcirc 3 \bigcirc 4 \bigcirc ungradable \bigcirc no symptom

modified Medical Research Council (mMRC) breathlessness scale

- 0. Breathlessness only with strenuous exercise
- 1. Breathlessness when hurrying or walking up a slight hill
- 2. Walks slower than people of the same age because of breathlessness or has to stop for breath when walking at own pace
- 3. Stops for breath after walking 100 yards or after a few minutes
- 4. Too breathless to leave house or breathless when dressing or undressing

□ Anxiety

 \bigcirc 1 \bigcirc 2 \bigcirc 3 \bigcirc 4 \bigcirc 5 \bigcirc ungradable \bigcirc no symptom

NCI Criteria

- 1: Mild symptoms; intervention not indicated
- 2: Moderate symptoms; limiting instrumental ADL
- 3: Severe symptoms; limiting self-care ADL; hospitalization not indicated
- 4: Life-threatening; hospitalization indicated
- 5: Death

T1 - REGULAR OPIOID DOSING DETAILS					
Total dose of REGULAR opioid given in the last 24 hours for breathlessness?					
Unit of Measure: (tick whichever applies)	○mg	○ mcg			
How long has the patient been on this REGULAR dose (days)					
T1- PRN/AS NEEDED OPIOID DOSING DETAILS					
Total Dose of PRN/as needed opioid administered in the last 24 hours for breathlessness?					
Unit of Measure: (tick whichever applies)	○mg	○ mcg			
How long has the patient been on this PRN dose (days)					
Based on your assessment at this time, was there any benefit	t?				
○ Yes ○ No					
T ₁ – Symptom/Harm Assessment Please grade all harms/toxicities regardless of whether they are attrib medication of interest or not; indicate that each harm has been assess square box above each					
□ Dizziness○ 1 ○ 2 ○ 3 ○ ungradable ○ No Symptom					
NCI Criteria 1.Mild unsteadiness or sensation of movement 2.Moderate unsteadiness or sensation of movement; limiting instrumental ADL 3.Severe unsteadiness or sensation of movement; limiting self-care ADL					
□ Nausea ○1 ○2 ○3 ○ ungradable ○ No Symptom					
NCI Criteria 1.Loss of appetite without alteration in eating habits 2.Oral intake decreased without significant weight loss, dehydration, or malnutrition 3.Inadequate oral caloric or fluid intake; tube feeding, TPN, or hospitalization indicates	ed				
☐ Somnolence ○ 1 ○ 2 ○ 3 ○ 4 ○ 5 ○ Ungradable ○ No Symptom					
 NCI Criteria 1. Mild but more than usual drowsiness or sleepiness 2. Moderate sedation; limiting instrumental ADL 3. Obtundation or stupor 4. Life-threatening consequences; urgent intervention indicated 5. Death 					

□ Confusion				
○ 1 ○ 2 ○ 3 ○ 4 ○ 5 ○ Ungradable ○ No Symptom				
NCI Criteria 1. Mild disorientation				
Moderate disorientation; limiting instrumental ADL				
3. Severe disorientation; limiting self-care ADL				
4. Life-threatening consequences threats of harm to self or others; hospitalization indicated 5. Death				
\square Constipation \bigcirc 1 \bigcirc 2 \bigcirc 3 \bigcirc 4 \bigcirc 5 \bigcirc ungradable \bigcirc no symptom				
○ 1 ○ 2 ○ 3 ○ 4 ○ 5 ○ ungradable ○ no symptom NCI Criteria				
1. Mild; asymptomatic or mild symptoms				
2. Moderate; minimal; local or non-invasive intervention indicated 3. Sovere or modically significant but not immediately life threatening.				
Severe or medically significant but not immediately life threatening Life threatening consequences; urgent intervention indicated				
5. Death				
What is the patient's respiratory rate (breaths/min)				
(breadis/illiii)				
□ Other harm (only if applicable – can be related or unrelated to the medication)				
Please specify other harm here				
Other harms grade:				
\bigcirc 1 \bigcirc 2 \bigcirc 3 \bigcirc 4 \bigcirc 5 \bigcirc Ungradable				
☐ Additional other harm (only if applicable – can be related or unrelated to the				
medication)				
Please specify additional other harm here				
Additional other harm grade:				
\bigcirc 1 \bigcirc 2 \bigcirc 3 \bigcirc 4 \bigcirc 5 \bigcirc Ungradable				
Tick ✓ Which symptom/harm is the most troublesome? (excluding the				
target symptoms of breathlessness and anxiety) (Tick one only)				
B: :				

Tick ✓	Which symptom/harm is the most troublesome? (excluding the target symptoms of breathlessness and anxiety) (Tick one only)
	Dizziness
	Nausea
	Somnolence
	Confusion
	Respiratory Depression
	Constipation
	Other harm
	Additional other harm
	Not applicable

Tick 'yes', 'no', or 'don't know' for each question below.

If the symptom was present at baseline, and grading remains unchanged, answering the Naranjo questions is not required.

Yes	No	Don't know	
			1. Did the adverse reaction appear after the suspected
			drug was given?
			2. Did the adverse reaction improve when the drug
			was discontinued, or a specific antagonist was given?
			3. Are there alternative causes (other than the drug)
			that could on their own have caused the reaction?
			4. Did the patient have a similar reaction to the same
			or similar drug in any previous exposure?
			5. Was the adverse event confirmed by any objective
			evidence?

HARM ASSESSMENT FOLLOW-UP

What is the intended treatment based on the T₁ assessment?

Tick yes or no to all

Yes	No	Changes to opioid for breathlessness
		No change to opioid/continue current dose
		Opioid for breathlessness ceased (complete cessation form pg. 21)
		Opioid dose decreased/reduced
		Opioid dose increased
		Current opioid ceased and new opioid started. Please specify new opioid, the reason for the change, and the dose & frequency:
		Has a non-opioid medication been added to treat a specific harm? If yes, please specify medication and dose:

	new Day 2 tota harm assessm		f REGULAR		
Unit of Measure: (Tick whichever applies)				○ mg (mcg
What is the new Day 2 PRN/as needed dose after harm assessment?					
Unit of Measure: (Tick whichever applies)				mcg	
Frequency of PRN dose prescribed (Please circle frequency, or indicate other)					
Q1h	Q2h	Q3h	Q4h	Q6h	Q8h
Q12	Other: Please	specify here:			
Maximum number of PRN doses allowed in 24-hour period:					
Based on the assessment today, has the harm resolved?					
○ Yes ○ No ○ N/A					

T₂ 7-14 days after baseline

Tick ✓	T ₂ : Assessed/Not assessed reason
	Assessed today (continue to complete T ₂) OR
	Died – record date of death below
	Not able to be contacted / located
	Too unwell
	Other

*End survey here

Date of T ₂ Assessment	DD/MM/YYYY
Time of Assessment (24 hr. clock)	HH:MM

If today's assessment is not 7-14 days after baseline, please give reason below e.g., standard practice is different.

T ₂ - REGULAR OPIOID DOSING DETAILS		
Has the <i>REGULAR</i> opioid been changed to a different op O Yes - please complete REGULAR opioid changes below	oioid sind	ce T1?
Total dose of <i>regular</i> opioid given in the last 24 hours for breathlessness?		
Unit of Measure: (tick whichever applies)	○mg	○ mcg
How long has the patient been on this dose (days)		
T ₂ - PRN/AS NEEDED OPIOID DOSING DETAILS		
Has the PRN opioid been changed to a different opioid	since T1?	
○ Yes - please complete PRN opioid changes below ○	No	
Total Dose of <i>PRN/as needed</i> opioid administered in the last 24 hours for breathlessness?		
Unit of Measure: Tick whichever applies	○mg	○ mcg
How long has the patient been on this dose (days)		

REGULAR OPIOID CHANGES Only complete if different to T_1 Tick ✓ Name of regular opioid for breathlessness Morphine Oxycodone Fentanyl Buprenorphine Tramadol Tapentadol Codeine Hydromorphone Other(s); please specify: Tick ✓ **Route of administration/formulation** Oral immediate release solution Oral immediate release tablet Oral extended-release tablet Subcutaneous Intravenous Transdermal Transmucosal Other; please specify: Total dose of REGULAR opioid given in the last 24 hours for breathlessness **Unit of Measure:** \bigcirc mg \bigcirc mcg Tick whichever applies

AS NEEDED (PRN) OPIOID CHANGES Only complete if different to T_1) Tick ✓ Indicate which PRN opioid commenced for breathlessness. Morphine Oxycodone Fentanyl Buprenorphine Tramadol **Tapentadol** Codeine Hydromorphone Other(s); please specify: Tick ✓ **Route of administration/formulation** Oral immediate release solution Oral immediate release tablet Oral extended-release tablet Subcutaneous Intravenous Transdermal Transmucosal Other; please specify: PRN dose prescribed by doctor **Unit of Measure:** \bigcirc mg \bigcirc mcg Tick whichever applies Frequency of PRN dose prescribed (Please circle frequency, or indicate other) Q4h Q1h Q2h Q3h Q6h Q8h Q12 Other: Please specify here: Maximum number of PRN doses allowed in 24-hour period:

Tick ✓	Australian Modified Karnofsky Performance Scale (AKPS)
	100 - Normal; no complaints; no evidence of disease
	90 - Able to carry on normal activity; minor sign of symptoms of disease
	80 - Normal activity with effort; some signs or symptoms of disease
	70 - Cares for self; unable to carry on normal activity or to do active work
	60 - Requires occasional assistance but is able to care for most needs
	50 - Requires considerable assistance and frequent medical care
	40 - In bed more than 50% of the time
	30 - Almost completely bedfast
	20 - Totally bedfast and requiring extensive nursing care by professionals and/or family
	10 - Comatose or barely rousable
	0 - Dead
	Not able to determine

Symptom Severity Score	om Severity Scores
------------------------	--------------------

Please grade both symptoms; indicate that each harm has been assessed by ticking the
square box above each.
□ Breathlessness □ 1 □ 2 □ 3 □ 4 □ ungradable □ no symptom modified Medical Research Council (mMRC) breathlessness scale 0. Breathlessness only with strenuous exercise 1. Breathlessness when hurrying or walking up a slight hill 2. Walks slower than people of the same age because of breathlessness or has to stop for breath when walking at own pace
3. Stops for breath after walking 100 yards or after a few minutes
4. Too breathless to leave house or breathless when dressing or undressing
□ Anxiety ○ 1 ○ 2 ○ 3 ○ 4 ○ 5 ○ ungradable ○ no symptom
NCI Criteria 1: Mild symptoms; intervention not indicated 2: Moderate symptoms; limiting instrumental ADL 3: Severe symptoms; limiting self-care ADL; hospitalization not indicated 4: Life-threatening; hospitalization indicated 5: Death
Based on your assessment at this time was there any benefit?
○ Yes ○ No
T ₂ – Symptom/Harm Assessment (Please grade all harms/toxicities regardless of whether they are attributable to the medication of interest or not; indicate that each harm has been assessed by ticking the square box next to each)
□ Dizziness○ 1 ○ 2 ○ 3 ○ ungradable ○ No Symptom
NCI Criteria 1.Mild unsteadiness or sensation of movement 2.Moderate unsteadiness or sensation of movement; limiting instrumental ADL 3.Severe unsteadiness or sensation of movement; limiting self-care ADL

□ Nausea				
○ 1 ○ 2 ○ 3 ○ ungradable ○ No Symptom				
NCI Criteria				
1.Loss of appetite without alteration in eating habits				
2.Oral intake decreased without significant weight loss, dehydration, or malnutrition				
3.Inadequate oral caloric or fluid intake; tube feeding, TPN, or hospitalization indicated				
□ Somnolence				
○ 1 ○ 2 ○ 3 ○ 4 ○ 5 ○ Ungradable ○ No Symptom				
NCI Criteria				
1. Mild but more than usual drowsiness or sleepiness				
2. Moderate sedation; limiting instrumental ADL				
Obtundation or stupor Life-threatening consequences; urgent intervention indicated				
5. Death				
□ Confusion				
○ 1 ○ 2 ○ 3 ○ 4 ○ 5 ○ Ungradable ○ No Symptom				
NCI Criteria				
Mild disorientation Moderate disorientation; limiting instrumental ADL				
3. Severe disorientation; limiting self-care ADL				
4. Life-threatening consequences threats of harm to self or others; hospitalization indicated				
5. Death				
□ Constipation				
○ 1 ○ 2 ○ 3 ○ 4 ○ 5 ○ ungradable ○ no symptom NCI Criteria				
1. Mild; asymptomatic or mild symptoms				
2. Moderate; minimal; local or non-invasive intervention indicated				
3. Severe or medically significant but not immediately life threatening				
4. Life threatening consequences; urgent intervention indicated				
5. Death				
What is the national exeminatory, rate				
What is the patient's respiratory rate				
(breaths/min)				
☐ Other harms (only if applicable – can be related or unrelated to the medication)				
Please specify other harm here				
Other harms grade:				
Guide marmis grader				
\bigcirc 1 \bigcirc 2 \bigcirc 3 \bigcirc 4 \bigcirc 5 \bigcirc Ungradable				
☐ Additional other harm (only if applicable – can be related or unrelated to the				
medication)				
Please specify additional other harm here				
Additional other harm grade:				
$\bigcirc 1 \bigcirc 2 \bigcirc 3 \bigcirc 4 \bigcirc 5 \bigcirc U$ ngradable				

Tick ✓	Which symptom/harm is the most troublesome? (excluding the target symptoms of breathlessness and anxiety) (Tick one only)
	Dizziness
	Nausea
	Somnolence
	Confusion
	Respiratory Depression
	Constipation
	Other harm
	Additional other harm
	Not applicable

Tick 'yes', 'no', or 'don't know' for each question below.

If the symptom was present at baseline, and grading remains unchanged, answering the Naranjo questions is not required.

Yes	No	Don't know	
			1. Did the adverse reaction appear after the suspected drug was given?
			2. Did the adverse reaction improve when the drug was discontinued, or a specific antagonist was given?
			3. Are there alternative causes (other than the drug) that could on their own have caused the reaction?
			4. Did the patient have a similar reaction to the same or similar drug in any previous exposure?
			5. Was the adverse event confirmed by any objective evidence?

HARM ASSESSMENT FOLLOW-UP

What is	What is the intended treatment based on today's T ₂ assessment?					
Tick yes	Tick yes or no to all					
Yes	No	Changes to opioid for breathlessness				
		No change to opioid/continue current dose				
		Opioid for breathlessness ceased (complete cessation form pg. 21)				
		Opioid dose decreased/reduced				
		Opioid dose increased				
		Current opioid ceased and new opioid started. Please specify new opioid, the reason for the change, and the dose & frequency:				
		Has a non-opioid medication been added to treat a specific harm? If yes, please specify medication and dose:				

	new 12 total 2 pioid after har	•				
Unit of Measure:) m.a	Omag
Tick whichev	er applies) mg	○ mcg
	new T ₂ PRN/a assessment?	s needed pres	cribed dose			
Unit of Mea	sure:				○mg	∩ mcg
Tick whichev	er applies				Unig) meg
Frequency	of PRN dose pr	escribed				
Circle freque	ncy or indicate of	ther				
Q1h	Q2h	Q3h	Q4h		Q6h	Q8h
Q12	Q12 Other: Please specify here:					
Maximum r	Maximum number of PRN doses allowed in 24-hour period					
Based on the assessment today, has the harm resolved?						
○ Yes ○	No ON/A					

Medication Cessation Complete this page if the intervention/medication of interest is ceased at any point during the study period					
Date of	Assessment (medication cessation) DD/MM/YYYY				
Tick ✓	Medication was ceased (related to indication of interest)				
TICK '	Symptom/s resolved; please indicate date symptom resolved:				
	Symptom/s continued unchanged				
	Symptom/s worsened; please grade below:				
□ Breath	nlessness (0 = nil criteria observed) $1 \bigcirc 2 \bigcirc 3 \bigcirc 4 \bigcirc 5$				
NCI Criteria 1: Shortnes 2: Shortnes 3: Shortnes					
\bigcirc 0 \bigcirc	1 02 03 01 03				
2: Moderate	a: enptoms; intervention not indicated e symptoms; limiting instrumental ADL eymptoms; limiting self-care ADL; hospitalisation not indicated 4: Life-threatening; hospitalisation				
Tick ✓	Intervention/medication was ceased (related to other reasons)				
	Harm/toxicity				
	Patient unable to take medication due to swallowing difficulty Patient refused to take medication				
	Other: please specify:				
·					
What treatment did you subsequently initiate following the cessation of the intervention/medication?					

Ad hoc A - Unscheduled Harm/Toxicity Assessment **Date of Assessment Harm/toxicity Assessment** Symptom Severity Scores Please grade all harms; indicate that each harm has been assessed by ticking the square box above each □ Breathlessness \bigcirc 2 \bigcirc 3 ○ ungradable ○ no symptom modified Medical Research Council (mMRC) breathlessness scale 0. Breathlessness only with strenuous exercise 1. Breathlessness when hurrying or walking up a slight hill 2. Walks slower than people of the same age because of breathlessness or has to stop for breath when walking at own pace 3. Stops for breath after walking 100 yards or after a few minutes 4. Too breathless to leave house or breathless when dressing or undressing ☐ Anxiety \bigcirc ungradable \bigcirc no symptom \bigcirc 1 \bigcirc 2 \bigcirc 3 \bigcirc 4 \bigcirc 5 NCI Criteria 1: Mild symptoms; intervention not indicated 2: Moderate symptoms; limiting instrumental ADL 3: Severe symptoms; limiting self-care ADL; hospitalization not indicated 4: Life-threatening; hospitalization indicated 5: Death Symptom/Harm Assessment (Please grade all harms/toxicities regardless of whether they are attributable to the medication of interest or not; indicate that each harm has been assessed by ticking the square box next to each) □ Dizziness \bigcirc 3 \bigcirc 1 \bigcirc 2 ○ ungradable ○ No Symptom NCI Criteria 1.Mild unsteadiness or sensation of movement 2. Moderate unsteadiness or sensation of movement; limiting instrumental ADL 3. Severe unsteadiness or sensation of movement; limiting self-care ADL □ Nausea \bigcirc 1 ○ ungradable ○ No Symptom \bigcirc 2 \bigcirc 3 1.Loss of appetite without alteration in eating habits 2. Oral intake decreased without significant weight loss, dehydration, or malnutrition 3. Inadequate oral caloric or fluid intake; tube feeding, TPN, or hospitalization indicated

□ Somnolence					
1 0 2 0 3 0 4 0 5 0 Ungradable 0 No Symptom					
NCI Criteria 1. Mild but more than usual drowsiness or sleepiness 2. Moderate sedation; limiting instrumental ADL 3. Obtundation or stupor 4. Life-threatening consequences; urgent intervention indicated 5. Death					
□ Confusion					
○1 ○2 ○3 ○4 ○5 ○ Ungradable ○ No Symptom					
 NCI Criteria 1. Mild disorientation 2. Moderate disorientation; limiting instrumental ADL 3. Severe disorientation; limiting self-care ADL 4. Life-threatening consequences threats of harm to self or others; hospitalization indicated 5. Death 					
☐ Constipation					
○ 1 ○ 2 ○ 3 ○ 4 ○ 5 ○ ungradable ○ no symptom NCI Criteria					
1. Mild; asymptomatic or mild symptoms 2. Moderate; minimal; local or non-invasive intervention indicated 3. Severe or medically significant but not immediately life threatening 4. Life threatening consequences; urgent intervention indicated 5. Death					
What is the patient's respiratory rate					
(breaths/min)					
\square Other harms (if they have been experienced)					
Please specify other harm:					
Other harms grade:					
○ 1 ○ 2 ○ 3 ○ 4 ○ 5 ○ Ungradable					
□ Additional other harms (if they have been experienced) Please specify additional other harm:					
Additional other harm grade:					
○ 1 ○ 2 ○ 3 ○ 4 ○ 5 ○ Ungradable					

Tick ✓	Which symptom/harm is the most troublesome? (excluding the target symptoms of breathlessness and anxiety) (Tick one only)
	Dizziness
	Nausea
	Somnolence
	Confusion
	Respiratory Depression
	Constipation
	Other harm
	Additional other harm
	Not applicable

Tick 'yes', 'no', or 'don't know' for each question below.

If the symptom was present at baseline and grading remains unchanged, answering the Naranjo questions is not required.

Yes	No	Don't know	
			1. Did the adverse reaction appear after the suspected drug was given?
			2. Did the adverse reaction improve when the drug was discontinued, or a specific antagonist was given?
			3. Are there alternative causes (other than the drug) that could on their own have caused the reaction?
			4. Did the patient have a similar reaction to the same or similar drug in any previous exposure?
			5. Was the adverse event confirmed by any objective evidence?

Ad hoc B - Unscheduled Harm/Toxicity Assessment **Date of Assessment Harm/toxicity Assessment Symptom Severity Scores** Please grade all harms; indicate that each harm has been assessed by ticking the square box above each. □ Breathlessness \bigcirc 4 ○ ungradable ○ no symptom modified Medical Research Council (mMRC) breathlessness scale 0. Breathlessness only with strenuous exercise 1. Breathlessness when hurrying or walking up a slight hill 2. Walks slower than people of the same age because of breathlessness or has to stop for breath when walking at own pace 3. Stops for breath after walking 100 yards or after a few minutes 4. Too breathless to leave house or breathless when dressing or undressing ☐ Anxiety \bigcirc 1 \bigcirc 2 \bigcirc 3 \bigcirc 4 \bigcirc 5 \bigcirc ungradable \bigcirc no symptom NCI Criteria 1: Mild symptoms; intervention not indicated 2: Moderate symptoms; limiting instrumental ADL 3: Severe symptoms; limiting self-care ADL; hospitalization not indicated 4: Life-threatening; hospitalization indicated 5: Death Symptom/Harm Assessment Please grade all harms/toxicities regardless of whether they are attributable to the medication of interest or not; indicate that each harm has been assessed by ticking the square above each. □ Dizziness \bigcirc 1 \bigcirc 2 \bigcirc 3 ○ ungradable ○ No Symptom NCI Criteria 1.Mild unsteadiness or sensation of movement 2. Moderate unsteadiness or sensation of movement; limiting instrumental ADL 3. Severe unsteadiness or sensation of movement; limiting self-care ADL □ Nausea \bigcirc 1 \bigcirc 2 \bigcirc 3 ○ ungradable ○ No Symptom NCI Criteria 1.Loss of appetite without alteration in eating habits 2. Oral intake decreased without significant weight loss, dehydration, or malnutrition 3.Inadequate oral caloric or fluid intake; tube feeding, TPN, or hospitalization indicated

○ 1 ○ 2 ○ 3 ○ 4 ○ 5 ○ Ungradable ○ No Symptom				
NCI Criteria 1. Mild but more than usual drowsiness or sleepiness 2. Moderate sedation; limiting instrumental ADL 3. Obtundation or stupor 4. Life-threatening consequences; urgent intervention indicated 5. Death				
☐ Confusion ○ 1 ○ 2 ○ 3 ○ 4 ○ 5 ○ Ungradable ○ No Symptom				
 NCI Criteria 1. Mild disorientation 2. Moderate disorientation; limiting instrumental ADL 3. Severe disorientation; limiting self-care ADL 4. Life-threatening consequences threats of harm to self or others; hospitalization indicated 5. Death 				
□ Constipation○ 1○ 2○ 3○ 4○ 5○ ungradable○ no symptom				
NCI Criteria 1. Mild; asymptomatic or mild symptoms 2. Moderate; minimal; local or non-invasive intervention indicated 3. Severe or medically significant but not immediately life threatening 4. Life threatening consequences; urgent intervention indicated 5. Death				
What is the patient's respiratory rate (breaths/min)				
$\ \square$ Other harms (if they have been experienced)				
Please specify other harm here				
Other harms grade:				
O1 O2 O3 O4 O5 O Ungradable				
☐ Additional other harms (if they have been experienced)				
Please specify additional other harm here Additional other harm grade:				
○1 ○2 ○3 ○4 ○5 ○ Ungradable				

Tick ✓	Which symptom/harm is the most troublesome? (excluding the target symptoms of breathlessness and anxiety) (Tick one only)
	Dizziness
	Nausea
	Somnolence
	Confusion
	Respiratory Depression
	Constipation
	Other harm
	Additional other harm
	Not applicable

Tick 'yes', 'no', or 'don't know' for each question below.

If the symptom was present at baseline, and grading remains unchanged, answering the Naranjo questions is not required.

Yes	No	Don't know	
			1. Did the adverse reaction appear after the suspected drug was given?
			2. Did the adverse reaction improve when the drug was discontinued, or a specific antagonist was given?
			3. Are there alternative causes (other than the drug) that could on their own have caused the reaction?
			4. Did the patient have a similar reaction to the same or similar drug in any previous exposure?
			5. Was the adverse event confirmed by any objective evidence?

Ad hoc C - Unscheduled Harm/Toxicity Assessment **Date of Assessment** Harm/toxicity Assessment (Please grade all harms; indicate that each harm has been assessed by ticking the square box next to each) Symptom Severity Scores Please grade all harms; indicate that each harm has been assessed by ticking the square box above each ☐ Breathlessness \bigcirc 2 \bigcirc 3 \bigcirc 4 ○ ungradable ○ no symptom modified Medical Research Council (mMRC) breathlessness scale 0. Breathlessness only with strenuous exercise 1. Breathlessness when hurrying or walking up a slight hill 2. Walks slower than people of the same age because of breathlessness or has to stop for breath when walking at own pace 3. Stops for breath after walking 100 yards or after a few minutes 4. Too breathless to leave house or breathless when dressing or undressing □ Anxiety ○ 2 ○ 3 ○ 4 ○ 5 ○ ungradable ○ no symptom \bigcirc 1 NCI Criteria 1: Mild symptoms; intervention not indicated 2: Moderate symptoms; limiting instrumental ADL 3: Severe symptoms; limiting self-care ADL; hospitalization not indicated 4: Life-threatening; hospitalization indicated 5: Death Symptom/Harm Assessment Please grade all harms/toxicities regardless of whether they are attributable to the medication of interest or not; indicate that each harm has been assessed by ticking the square box next to each □ Dizziness \bigcirc 1 ○ 3 ○ ungradable ○ No Symptom 1.Mild unsteadiness or sensation of movement 2. Moderate unsteadiness or sensation of movement; limiting instrumental ADL 3. Severe unsteadiness or sensation of movement; limiting self-care ADL □ Nausea $\bigcirc 1 \bigcirc 2$ ○ 3 ○ ungradable ○ No Symptom

1.Loss of appetite without alteration in eating habits

2.Oral intake decreased without significant weight loss, dehydration, or malnutrition 3.Inadequate oral caloric or fluid intake; tube feeding, TPN, or hospitalization indicated

NCI Criteria

□ Somnolence					
○ 1 ○ 2 ○ 3 ○ 4 ○ 5 ○ Ungradable ○ No Symptom NCI Criteria					
1. Mild but more than usual drowsiness or sleepiness 2. Moderate sedation; limiting instrumental ADL 3. Obtundation or stupor 4. Life-threatening consequences; urgent intervention indicated 5. Death					
□ Confusion					
○ 1 ○ 2 ○ 3 ○ 4 ○ 5 ○ Ungradable ○ No Symptom					
 NCI Criteria 1. Mild disorientation 2. Moderate disorientation; limiting instrumental ADL 3. Severe disorientation; limiting self-care ADL 4. Life-threatening consequences threats of harm to self or others; hospitalization indicated 5. Death 					
☐ Constipation ○ 1 ○ 2 ○ 3 ○ 4 ○ 5 ○ ungradable ○ no symptom					
○ 1 ○ 2 ○ 3 ○ 4 ○ 5 ○ ungradable ○ no symptom NCI Criteria					
1. Mild; asymptomatic or mild symptoms 2. Moderate; minimal; local or non-invasive intervention indicated 3. Severe or medically significant but not immediately life threatening 4. Life threatening consequences; urgent intervention indicated 5. Death					
What is the patient's respiratory rate (breaths/min)					
☐ Other harms (if they have been experienced) Please specify other harm here					
Other harms grade:					
O 1 O 2 O 3 O 4 O 5 O Ungradable					
☐ Additional other harms (if they have been experienced) Please specify additional other harm here					
Additional other harm grade:					
○ 1 ○ 2 ○ 3 ○ 4 ○ 5 ○ Ungradable					

Tick ✓	Which symptom/harm is the most troublesome? (excluding the target symptoms of breathlessness and anxiety) (Tick one only)			
	Dizziness			
	Nausea			
	Somnolence			
	Confusion			
	Respiratory Depression			
	Constipation			
	Other harm			
	Additional other harm			
	Not applicable			

Tick 'yes', 'no', or 'don't know' for each question below.

If the symptom was present at baseline, and grading remains unchanged, answering the Naranjo questions is not required.

Yes	No	Don't know	
			1. Did the adverse reaction appear after the suspected drug was given?
			2. Did the adverse reaction improve when the drug was discontinued, or a specific antagonist was given?
			3. Are there alternative causes (other than the drug) that could on their own have caused the reaction?
			4. Did the patient have a similar reaction to the same or similar drug in any previous exposure?
			5. Was the adverse event confirmed by any objective evidence?